U.S. Physical Therapy, Inc. (USPH) 股票分析

公司概述

U.S. Physical Therapy, Inc. operates as a specialized provider within the healthcare sector, specifically focusing on the medical care facilities industry by managing a network of outpatient physical therapy clinics. The company's core business activities encompass the delivery of pre-and post-operative care and treatment protocols, alongside industrial injury prevention services, primarily targeting orthopedic conditions. With a market capitalization of $1.17B and an annual revenue of $773.34M, the firm demonstrates a significant operational footprint supported by a workforce of 4,653 employees. These valuation and revenue metrics position the entity as a mid-to-large-cap player within the physical therapy segment, indicating a substantial scale that allows for diversified operations across its two primary segments. The combination of a $1.17B market cap and $773.34M in trailing twelve-month revenue suggests the company holds a mature market presence, balancing its extensive employee base with solid income generation capabilities in the competitive healthcare landscape.

财务健康

The company reported a trailing twelve-month revenue of $773.34M, generating a net income of $21.57M and an EBITDA of $103.09M, which highlights a distinct gap between top-line revenue and bottom-line profitability. This substantial disparity reveals a heavy cost structure where operating expenses, likely including labor and overhead for a large employee base, consume a significant portion of earnings before interest and taxes. The firm maintains a free cash flow of $73.92M, providing a critical buffer that supports financial flexibility for capital expenditures, debt servicing, or strategic reinvestment without immediate reliance on external financing. Profitability analysis shows a gross margin of 22.1%, an operating margin of 10.9%, and a profit margin of 5.1%, indicating that while the company generates revenue efficiently at the gross level, non-operating costs or taxes further compress the final return to shareholders. On the balance sheet, the company holds $36.31M in cash against $315.16M in debt, resulting in a debt-to-equity ratio of 40.92, which characterizes a leveraged financial structure rather than a conservative one. Liquidity is assessed via a current ratio of 1.01, signaling that the company's current assets are only marginally higher than its current liabilities, suggesting tight short-term liquidity management. Return metrics further illuminate management effectiveness, with a return on equity of 7.6% and a return on assets of 4.3%, reflecting moderate efficiency in generating returns relative to the capital invested and the total asset base utilized.

估值评估

Valuation metrics indicate a trailing P/E ratio of 54.04 compared to a forward P/E of 23.17, implying that the market currently prices in a significant expected improvement in future earnings growth relative to historical performance. The price-to-book ratio stands at 2.44, suggesting that the market assigns a substantial premium to the company's tangible assets, valuing it at more than twice its book value. Alternative valuation indicators include a price-to-sales ratio of 1.51 and an EV/EBITDA of 16.81, which provide context on revenue quality and enterprise value relative to operating cash generation, suggesting the market values the firm's revenue stream and operational leverage moderately. The stock has traded between a 52-week high of $93.50 and a 52-week low of $64.55, and without the current share price explicitly listed in the provided facts, the precise percentage deviation from these bounds cannot be calculated; however, the range defines the recent volatility envelope within which the stock has operated. The beta of 1.35 indicates that the stock's price volatility is 35% higher than the broader market, meaning the security is more sensitive to general market fluctuations than a beta-neutral asset.

Growth & Income

Revenue growth for the trailing twelve months stands at 12.5%, while earnings growth is listed as N/A, preventing a direct year-over-year comparison of profitability expansion against top-line expansion. The absence of specific earnings growth data limits the ability to determine if earnings are growing faster or slower than revenue, but the revenue expansion suggests a positive trajectory in patient volume or pricing power. As a dividend payer, the company offers a yield of 2.4% with a payout ratio of 126.8%, indicating that the dividend is currently funded from sources beyond just the reported net income, such as cash flow or retained earnings from prior periods. The payout ratio exceeding 100% suggests that the dividend sustainability relies heavily on the company's strong free cash flow generation of $73.92M rather than current net income alone. Overall, the growth and income profile reflects a mature company delivering steady revenue expansion and a consistent dividend yield, though the high payout ratio necessitates close monitoring of cash flow stability to ensure long-term dividend security.